The Pacific Northwest Hypertrophic Cardiomyopathy Summit
Thank you for attending the summit, which provided attendees with an opportunity to learn the clinical, morphologic and genetic spectrum of hypertrophic cardiomyopathy (HCM). Description: The program will explore the diverse views on the clinical presentation, contemporary imaging and diagnostics, natural history and assessment of risk for sudden death. This CME accredited summit is designed for cardiologists, internists, pediatricians and other health care professionals with an interest in hypertrophic cardiomyopathy. There will be a parallel patient forum that is designed to educate patients on their disease, facilitate local networking and support for families, and provide a forum for questions and answers from local and national experts.
- Regional cardiologists, internists, pediatricians and other health care professionals with an interest in HCM.
- Clinicians and basic researchers directly involved with cardiomyopathies.
- Patients and family members diagnosed with or involved in the care of patients with HCM.
- Identify the clinical, morphologic and genetic spectrum of HCM.
- Explore the diverse views on the natural history and assessment of risk for sudden death.
- Review contemporary management strategies for high--‐risk and other patient subgroups, including surgical septal myectomy, alcohol septal ablation, pacing, and prevention of sudden death with implantable defibrillators.
- Assess and determine appropriate management of heart failure and arrhythmias, including atrial fibrillation and ventricular achyarrhythmia.
- Identify mechanisms responsible for adverse clinical events and natural history.
- Learn the role of new diagnostic modalities including magnetic resonance imaging (MRI), positron emission tomography (PET), and advanced echocardiographic techniques.
- Understand the significance and occurrence of left ventricular outflow obstruction.
- Learn about key developments in risk assessment for sudden death, based on detection of myocardial fibrosis with MRI.
Oregon Health & Science University is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
OHSU School of Medicine, Division of CME, designates this live activity or a maximum of 9 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Oregon Health & Science University intends to provide balanced, independent, objective and scientifically rigorous educational programming. All faculty and planning committee members participating in sponsored activities and their spouse/partner are required to disclose to the activity audience any real or apparent conflict(s) of interest related to the content of this summit.
Friday, November 1, 2013
Saturday, November 2, 2013
|08:00 - 09:00||Breakfast and Patient Registration|
|09:00 - 13:00
Living with hypertrophic cardiomyopathy
|Lisa Salberg, CEO of the Hypertrophic Cardiomyopathy Association|
|09:00 - 09:45
||The utility of cardiac MRI in the evaluation of HCM and risk stratification for SCD in HCM||Ed Kahl, M.D.|
|09:45 - 10:00||The utility of cardiac MRI in the evaluation of HCM and risk stratification for SCD in HCM||Martin Maron, M.D.|
|10:00 - 10:45
||HCM in the pediatric population||Seshadri Balaji, M.D.|
|10:00 - 10:45||Break|
|11:00 - 11:45||Contemporary risk stratification and therapies for the prevention of sudden cardiac death||Eric Stecker, M.D.|
|11:45 - 12:20||Screnning Strategies Prior to Participation in Competitive Athletics||James Chesnutt, M.D.|
|12:20 - 13:00||Management options for Atrial Fibrillation in Patients with HCM||Joaquin Cigarroa, M.D.|